2026-08-11
12 分钟More time connecting brands with the moments and fandoms that matter most.
Learn more at Accenture.com slash Spotify.
Every parent's worst nightmare is their child getting a brain tumour.
Brain tumours are the most common type of solid tumour in children
and also the most deadly because they're notoriously hard to treat.
But happily, there is now some hope on the horizon with a brand new kind of immunotherapy resulting
in remarkable recoveries in a handful of children with terminal brain tumours in a small clinical trial.
This story is personal for me because my young nephew, Jeremiah,
he died 16 years ago from a brain tumour before anything like this was possible.
From New Scientist, this is the world, the universe and us.
And I'm reporter James Woodford.
I'm joined by my colleague, Alice Klein, who has just written a story about this promising new treatment.
Alice, how does this all work?
Yeah, so the name of the treatment is tumor-associated antigen T-cell therapy, which is a bit of a mouthful.
So it's called TAAT for short.
It basically involves taking a child's immune cells out of their body.
Training them in the lab to become better
and stronger at fighting their brain tumour and then putting them back into the child.
Okay, because our immune systems do naturally try to fight cancers in the body, right?
So sometimes they just need some extra help?